This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Obagi® Medical Products Presents Study Results At American Academy Of Dermatology

Stocks in this article: OMPI

Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, released the results of three new studies this weekend at the American Academy of Dermatology meeting in San Diego, CA. The studies explored the use of the Nu-Derm System with tretinoin, as prescribed by the investigators, in the treatment of melasma and hyperpigmentation in patients with Fitzpatrick skin types III – VI. Each study evaluated the efficacy and tolerability of the treatment on the skin as well as its effects on the patients’ emotional well-being.

“Nu-Derm with tretinoin has long been a go-to regimen, particularly in difficult-to-treat melasma, for many dermatologists,” Jim Hartman, Vice President Global Marketing and Business Development at Obagi, said. “Our objective in partnering with these respected experts in the field of dermatology for these studies was to provide clinical proof that Nu-Derm, in combination with varying percentages of tretinoin, based on recommendations from key opinion leaders, is a valid, effective option in many skin types, including darker skin patients, as well as in patients more sensitive to irritation. The results presented this weekend indicate that we successfully met that objective.”

The 75 patients in the three studies followed a morning regimen that included a foaming gel cleanser, toner, four percent hydroquinone product, exfoliation enhancer and a sunscreen with SPF 35. The evening regimen consisted of a foaming gel cleanser, toner and four percent hydroquinone product mixed with a tretinoin cream at various percentages. Patients reported high levels of patient satisfaction and improved quality of life metrics across the studies.

The studies postered and affiliated investigators are as follows:

Study 4581 - Treatment of Moderate or Marked Melasma in Darker Skin with a Four Percent Hydroquinone Skin Care System Plus 0.025% Tretinoin Cream:

  • Lead investigator for Study 4581 is Pearl Grimes, MD (Los Angeles, CA)

Study 5131 - Treatment of Moderate or Marked Melasma with a Four Percent Hydroquinone Skin Care System Plus 0.1 Percent Tretinoin Cream: Comparison in Asian and Caucasian Patients:

  • Lead investigator for Study 5131 is Dr. Suzanne Bruce (Suzanne Bruce & Associates, PA; Houston, TX)

Study 5139 - Treatment of Moderate or Marked Melasma in Darker Skin with a Four Percent Hydroquinone Skin Care System Plus 0.05% Tretinoin Cream:

  • Lead investigators for Study 5139 are Michael Gold, MD (Nashville, TN), Marta Rendon, MD (Boca Raton, FL), Barry DiBernardo, MD (Monclair, NJ), Suzanne Bruce (Suzanne Bruce & Associates, PA; Houston, TX) and Chere Lucas-Anthony, MD (Boca Raton, FL)

The investigators reported considerable improvements in melasma and skin discoloration, in addition to high levels of patient satisfaction across all three studies.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,399.67 +19.26 0.12%
S&P 500 1,904.01 +17.25 0.91%
NASDAQ 4,316.0740 +57.6360 1.35%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs